Celgene Scientist II, Translational Research Hematology-Oncology in San Francisco, California
Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.
The Translational Scientist will contribute to developing strategy, and will be responsible for design and execution of lab experiments for translational studies supporting drug programs in late clinical development for hematological myeloid malignancies, including myelofibrosis, acute myeloid leukemia and myeloid dysplastic syndrome.
The ideal candidate will have translational/research experience in hematology-oncology, hands-on expertise in flow cytometry, drug assay development, CRO work, and in-depth understanding of in vivo pharmacology.
Responsibilities will include, but are not limited to, the following:o Develop strategy, design, execute and interpret lab experiments to characterize drug mechanisms of action and efficacy, understand mechanisms of resistance, and inform rational combinations for hematological malignancies.o Develop biochemistry and cell based assays to understand the effect of therapeutic drugs, as single agents and in combinations using primary hematopoietic cells, including stem cells and blood.o Process and analyze tissue samples and cell lines, including primary human and murine blood, bone marrow, and lymphoid tissues, utilizing FACS, lenti/retroviral transduction and varied assays to understand the biology of hematopoietic cells and the effect of drugs.o Utilize ex-vivo cultures and outsourced in vivo models to understand molecular and cellular aspects of hematological diseases, drug pharmacokinetics, pharmacodynamics and drug mechanisms of efficacy to inform clinical biomarkers to guide selection of drug dose-schedule.o Develop and review CRO and academic study proposals for in vitro and in vivo studies to evaluate drug candidates.o Interact with project teams, academic collaborators and CROs, and critically review data generated by contract labs and academic collaborators.o Lead scientifically in area of expertise and stay up-to-date with relevant clinical and non-clinical publications.o Present summaries of work at group meetings, internal forums and scientific conferences.o Author study reports, assay protocols, patent applications, peer-reviewed publications.
Skills/Knowledge Required:o Ph.D. degree in hematology, immunology, biochemistry, molecular or cellular biology, with at least 4 years of recent research or R&D experience in hematological diseases as a bench scientist, supported by publication record, ideally as first or senior author.o Hands-on experience with phenotypic and functional assays used in hematology-oncology with understanding of cellular, biochemical and molecular readouts: these include analysis of primary samples (e.g. blood, bone marrow, immune cells) by multi-color flow cytometry; transduction and differentiation of hematopoietic stem cells (HSC) and immune cells; colony forming unit assays and immune cell functional assays and establishment of primary co-culture systems.o Hands-on experience with drug assay development, including drug-target engagement, signaling, drug cytotoxicity, proliferation/apoptosis, multiplexed gene, cytokine, kinase profiling; ELISA/MSD, Western blot, RT-PCR, CRISPR/Cas9/RNAi; analysis of array and NGS data.o Comprehensive knowledge of pharmacology study design utilizing ex vivo and in vivo models for hematology and immuno-oncology research, including GEMMs, isogenic lines, and disseminated syngeneic and xenogeneic/xenograft models of hematological diseases.o Experience working with CROs.o Ability to develop a research plan, conduct experimental work with accurate and detailed record keeping.o Excellent organizational skills, with the ability to efficiently manage and prioritize multiple projects, internal and external collaborations.o Ability to interpret and summarize scientific data in an accurate, critical and concise manner.o The candidate will be a critical experimentalist, results oriented, who enjoys working in the lab and is comfortable working in a fast-paced environment.o Excellent oral and written communication skills.o Strong independent problem-solving skills.o Flexible and adaptable to changing priorities.o Must be willing to work with a highly motivated team.o Title commensurate with educational background and experience.
Ph.D. degree in hematology, immunology, biochemistry, molecular or cellular biology, with at least 4 years of recent and demonstrable research or R&D experience in hematological diseases as a bench scientist are required. Experience in hematology-oncology and/or myelofibrosis is a plus.
o Hands-on experience in advanced multicolor (+6) flow cytometry, drug assay development and CRO work are required. Experience in bioanalytical or clinical assay development is a plus.
o Candidates from Industry or Academic labs who fulfill above requirements and are directly engaged in clinical and/or translational research are highly encouraged to apply.
Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.